Guardant Health, Inc. (NASDAQ:GH) Short Interest Down 10.0% in December

Guardant Health, Inc. (NASDAQ:GH) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 8,250,000 shares, a decrease of 10.0% from the November 30th total of 9,170,000 shares. Based on an average daily trading volume, of 1,740,000 shares, the short-interest ratio is currently 4.7 days.

Analyst Ratings Changes

A number of analysts have recently commented on GH shares. The Goldman Sachs Group upped their price target on Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Leerink Partners cut their target price on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. JPMorgan Chase & Co. boosted their price target on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, Sanford C. Bernstein lowered their price objective on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. Fifteen research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $40.60.

Insider Buying and Selling

In other news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the sale, the director now owns 2,676 shares in the company, valued at $93,660. The trade was a 46.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Meghan V. Joyce sold 2,896 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the transaction, the director now owns 7,648 shares in the company, valued at $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,432 shares of company stock worth $175,423 in the last 90 days. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Guardant Health

Several hedge funds and other institutional investors have recently made changes to their positions in GH. JNBA Financial Advisors bought a new position in Guardant Health during the third quarter worth about $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Guardant Health in the third quarter valued at approximately $34,000. Quarry LP bought a new position in shares of Guardant Health during the 2nd quarter worth approximately $44,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Guardant Health during the 2nd quarter worth approximately $71,000. Finally, Nisa Investment Advisors LLC raised its stake in Guardant Health by 168.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company’s stock valued at $79,000 after acquiring an additional 2,153 shares during the period. 92.60% of the stock is owned by institutional investors.

Guardant Health Stock Up 0.0 %

NASDAQ:GH traded up $0.01 during trading hours on Wednesday, reaching $30.55. 1,605,590 shares of the stock were exchanged, compared to its average volume of 2,018,617. The stock has a market cap of $3.77 billion, a PE ratio of -7.21 and a beta of 1.26. Guardant Health has a twelve month low of $15.81 and a twelve month high of $38.53. The firm has a 50 day moving average of $30.51 and a 200 day moving average of $28.37. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The business had revenue of $191.48 million during the quarter, compared to analyst estimates of $170.49 million. During the same quarter in the previous year, the firm posted ($0.73) earnings per share. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. On average, equities analysts expect that Guardant Health will post -3.44 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.